US 12,188,004 B2
Cancer immunotherapy using transfusions of allogeneic, tumor-specific CD4+ T cells
Ephraim Joseph Fuchs, Owings Mills, MD (US); Heather Jill Symons, Annapolis, MD (US); and Lode Swinnen, Lutherville, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Feb. 10, 2020, as Appl. No. 16/786,761.
Application 16/786,761 is a continuation in part of application No. 15/939,059, filed on Mar. 28, 2018, abandoned.
Application 15/939,059 is a continuation of application No. 14/398,724, granted, now 9,931,359, issued on Apr. 3, 2018, previously published as PCT/US2013/032129, filed on Mar. 15, 2013.
Claims priority of provisional application 61/644,126, filed on May 8, 2012.
Prior Publication US 2020/0163997 A1, May 28, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 31/664 (2006.01); A61K 45/06 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01)
CPC C12N 5/0638 (2013.01) [A61K 31/664 (2013.01); A61K 39/461 (2023.05); A61K 39/4611 (2023.05); A61K 39/4615 (2023.05); A61K 39/4621 (2023.05); A61K 39/4622 (2023.05); A61K 39/46434 (2023.05); A61K 39/464401 (2023.05); A61K 39/464838 (2023.05); A61K 45/06 (2013.01); C12N 5/0087 (2013.01); A61K 2239/26 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/55 (2023.05); A61K 2239/57 (2023.05); Y02A 50/30 (2018.01)] 19 Claims
 
1. A method of making a lymphocyte composition for administration to a recipient comprising:
a) obtaining a peripheral blood cell composition from a donor, wherein the donor is vaccinated against an antigen present in the recipient, and wherein the peripheral blood cell composition contains CD8+ T-cells, CD4+ T-cells, and natural killer cells;
b) depleting the peripheral blood cell composition of the CD8+ T-cells, wherein depleting the peripheral blood cell composition of the CD8+ T-cells is reducing the number of CD8+ T-cells in the peripheral blood cell composition by at least one order of magnitude; and
c) expanding the CD4+ T cells specific to the antigen by culturing the CD4+ T cells with the antigen,
wherein the donor is partially HLA-mismatched, or HLA-haploidentical to the recipient, thereby making a lymphocyte composition.